Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05227352 · ClinicalTrials.gov registry record · NA

Bio-Experiential Spaces for Mental Health in Healthworkers

A NA study of Anxiety and Mental Health, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
85
Enrollment target
1
Study location

NCT05227352: Completed NA study of Anxiety and Mental Health, sponsored by Icahn School of Medicine at Mount Sinai.

NCT05227352 is a NA study of Anxiety and Mental Health that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 85 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05227352, a NA study of Anxiety and Mental Health, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
85 participants
Enrollment target
1
Study location

Study Summary

Recharge Rooms are immersive, biophilic private spaces designed to ameliorate trauma, anxiety, and stress. They feature multisensory input that is inspired by nature, as has previously been found to confer physiological benefits. These environments include silk imitation plants, projected scenes of soothing natural landscapes, low lighting that is tailored in color to match the landscapes that are being projected, high definition audio recordings of nature sounds paired with relaxing music, and infusion of essential oils and calming scents. The aim is to investigate the physiological and mental health outcomes that the short and long term exposure to these rooms have on healthcare workers. The data will be collected through online surveys. No identifiable information will be assessed or collected. The plan is to have 60 participants.

Primary Outcome

This assesses a variety of dimensions such as burnout, fatigue, mental and physical quality of life (QOL), depression and anxiety, and is used as a screening tool to assess residents at "high risk," who may be in distress, and who benefit from added resources and subsequent help seeking. It uses yes/no response categories, and a total score is calculated by adding the number of 'yes' responses. Full scale range from 0 to 7, with higher score indicating poorer health outcome, and a threshold scor

Interventions

  • BEHAVIORAL Biophilic design experience

Study Locations (1)

New York

  • Recharge Room at Mount Sinai Hospital - New York

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2022-09-27
Est. Completion 2025-01-08
Phase NA

What the finished NCT05227352 record still lists

NCT05227352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (81% lower).

The record links to 3 conditions, with Anxiety appearing as the primary indexed condition, and to 1 intervention - of which Biophilic design experience is the first listed.

NCT05227352 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05227352 about?

NCT05227352 is a clinical study titled "Bio-Experiential Spaces for Mental Health in Healthworkers". Recharge Rooms are immersive, biophilic private spaces designed to ameliorate trauma, anxiety, and stress. They feature multisensory input that is inspired by nature, as has previously been found to confer physiological benefits. These environments include silk imitation plants, projected scenes of ...

What is the current status of trial NCT05227352?

This trial is currently completed. It is a NA study. The enrollment target is 85 participants. The study started on 2022-09-27. Estimated completion is 2025-01-08.

What conditions does trial NCT05227352 study?

This clinical trial studies the following conditions: Anxiety, Mental Health, Cognition.

What interventions are being tested in trial NCT05227352?

The interventions under investigation include: Biophilic design experience (BEHAVIORAL).

Who is sponsoring clinical trial NCT05227352?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05227352 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05227352's enrollment target sits among peer trials

85 190th of 364 higher than 173 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00842283 · 85 participants

    Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

  • NCT02133196 · 85 participants · Phase 2

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • NCT03823144 · 85 participants · NA

    Intravital Microscopy in Human Solid Tumors

  • NCT03875638 · 85 participants · Phase 2

    Treating Hyperexcitability in AD With Levetiracetam

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05227352, the US trial registry maintained by the National Library of Medicine. NCT05227352 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.